<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Calcium gluconate: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Calcium gluconate: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Calcium gluconate: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9190" href="/d/html/9190.html" rel="external">see "Calcium gluconate: Drug information"</a> and <a class="drug drug_patient" data-topicid="11306" href="/d/html/11306.html" rel="external">see "Calcium gluconate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866175"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Calcium Sandoz</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1003045"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Hydrofluoric Acid</span>;</li>
<li>
<span class="list-set-name">Calcium Salt</span>;</li>
<li>
<span class="list-set-name">Electrolyte Supplement, Oral</span>;</li>
<li>
<span class="list-set-name">Electrolyte Supplement, Parenteral</span></li></ul></div>
<div class="block don drugH1Div" id="F53462391"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: Dosages are expressed in terms of the <span style="text-decoration: underline">calcium gluconate salt</span> or elemental calcium; use caution.</b></p>
<p style="text-indent:-2em;margin-left:6em;">1 gram calcium gluconate = 93 mg elemental calcium = 4.65 mEq calcium.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Adequate intake (AI): </b>
<b>Note:</b> Recommended intake from dietary sources (eg, breast milk, formula).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Dosage expressed as <b>elemental calcium</b>: Oral: 200 mg/day; requirements may vary on prematurity, postnatal age, and other clinical factors; serum calcium concentrations should be monitored closely to determine patient-specific needs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-IOM.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-IOM.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Enteral nutrition, maintenance requirement (dietary intake; formula, breastmilk):</b> Limited data available: Preterm neonates, birth weight &lt;2,000 g: Dosage expressed as <b>elemental calcium</b>: Oral: 150 to 220 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23629620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23629620'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia, adjunctive treatment:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Calcium is administered for myocardium stabilization and prevention of arrhythmias; must be used in conjunction with therapy to shift potassium intracellularly and/or eliminate potassium.</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates: Dose expressed as <b>calcium gluconate</b>: IV, Intraosseous: 60 to 100 mg/kg/<b>dose</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>). Doses as high as 200 mg/kg/<b>dose</b> infused over 30 to 60 minutes have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypermagnesemia, symptomatic with severe cardiac or neurologic manifestations:</b> Limited data available: Dose expressed as <b>calcium gluconate</b>: IV: 100 mg/kg/<b>dose</b> administered over 5 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Greenbaum.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Greenbaum.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypocalcemia</b>: Dose depends on clinical condition and serum calcium concentration; monitor closely:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Asymptomatic:</i> Limited data available: Preterm and term neonates: Dose expressed as <b>elemental calcium: </b>Oral: 50 to 75 mg/kg/day in 4 to 6 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Koo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Koo.1'])">Ref</a></span>). <b>Note:</b> In general, other calcium salts may be more preferable oral dosage forms in neonatal patients; however, the 10% calcium gluconate injection may be given orally (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7836618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7836618'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Symptomatic:</i> Dose expressed as <b>calcium gluconate</b>:</p>
<p style="text-indent:-2em;margin-left:6em;">Intermittent IV: 100 to 200 mg/kg/<b>dose</b>; additional doses may be administered every 6 hours as needed based on serum calcium concentrations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6716222','lexi-content-ref-31320908','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6716222','lexi-content-ref-31320908','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: Usual range: 10 to 33 mg/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6716222','lexi-content-ref-31320908','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6716222','lexi-content-ref-31320908','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe (</i>
<i>eg, seizures, tetany):</i> Dose expressed as <b>calcium gluconate</b>: IV: 100 to 200 mg/kg/<b>dose</b> over 10 to 20 minutes, may repeat in 10 to 20 minutes if no clinical response; follow initial dose(s) with a continuous infusion of 21 to 33 mg/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1','lexi-content-ref-20737250','lexi-content-ref-7836618','lexi-content-ref-Root.1','lexi-content-ref-31320908','lexi-content-ref-19411338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1','lexi-content-ref-20737250','lexi-content-ref-7836618','lexi-content-ref-Root.1','lexi-content-ref-31320908','lexi-content-ref-19411338'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition, maintenance calcium requirement:</b> Dose expressed as <b>elemental calcium</b>: IV: 2 to 4 <b>mEq</b>/kg/day as an additive to parenteral nutrition solution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15568296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15568296'])">Ref</a></span>). <b>Note:</b> Ca-P solubility issues may limit total daily dose provided in the TPN.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rickets, treatment:</b> Limited data available: <b>Note:</b> Treatment should also include adequate vitamin D supplementation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25266429','lexi-content-ref-26741135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25266429','lexi-content-ref-26741135'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Preterm and term neonates: Dose expressed as <b>elemental calcium</b>: Oral: Initial: 20 mg/kg/day, increased as tolerated to usual range of 60 to 70 mg/kg/day, usually administered in 4 to 6 divided doses; maximum daily dose: 80 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23629620','lexi-content-ref-Koo.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23629620','lexi-content-ref-Koo.1'])">Ref</a></span>). Alternatively, 30 to 75 mg/kg/day in 3 divided doses with initial doses at higher end of range and then titrated downward over 2 to 4 weeks has also been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23942432','lexi-content-ref-18676559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23942432','lexi-content-ref-18676559'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment in renal impairment:</b> Initiate at the lowest dose of the recommended dosage range; monitor serum calcium concentrations closely. Accumulation may occur with renal impairment and subsequent doses may require adjustment based on serum calcium concentrations.</p></div>
<div class="block dop drugH1Div" id="F144675"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: Dosages are expressed in terms of the <span style="text-decoration: underline">calcium gluconate salt</span> or elemental calcium; use caution. </b></p>
<p style="text-indent:-2em;margin-left:6em;">1 gram calcium gluconate = 93 mg elemental calcium = 4.65 mEq calcium.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6b66e573-4906-4244-b4df-daf6067c881e">Calcium channel blocker toxicity, hypotension/conduction disturbances</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calcium channel blocker toxicity, hypotension/conduction disturbances:</b> Infants, Children, and Adolescents: Dose expressed as <b>calcium gluconate</b>: IV: 60 mg/kg/<b>dose</b> administered over 30 to 60 minutes; maximum dose: 3,000 mg/<b>dose</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-31598101']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-31598101'])">Ref</a></span>); some experts recommend rapid administration (eg, infuse over 5 to 10 minutes) and recommend to repeat doses every 10 to 20 minutes up to 3 to 4 doses as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelson.1'])">Ref</a></span>); may also consider IV infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Konca.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Konca.1'])">Ref</a></span>). <b>Note:</b> Calcium chloride may provide a more rapid increase of ionized calcium in critically ill children. Calcium gluconate may be substituted if calcium chloride is not available or if administering through a peripheral line (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956230']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956230'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6033c440-aa05-49a9-9c8c-a0a7d1cc6d1e">Hydrofluoric acid burns, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hydrofluoric acid burns, treatment:</b> Limited data available: Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ: 5% to 10% solution: 0.5 <b>mL</b>/cm<sup>2</sup> of burned tissue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5479482','lexi-content-ref-15019125','lexi-content-ref-8540974','lexi-content-ref-Krenzelok.1999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5479482','lexi-content-ref-15019125','lexi-content-ref-8540974','lexi-content-ref-Krenzelok.1999'])">Ref</a></span>). Infiltration should be carried 0.5 cm away from the margin of the injured tissue into the surrounding uninjured areas. Repeat if pain recurs. Local anesthesia may be required to perform procedure; pain resolution is the therapeutic endpoint and if a local anesthetic is utilized, it may be difficult to determine the success of therapy. <b>Note:</b>
<b>Never</b> use calcium chloride for subcutaneous injection.</p>
<p style="text-indent:-2em;margin-left:4em;">Intra-arterial: Add 10 <b>mL</b> of a 10% solution to 50 mL of D5W. Infuse over 4 hours into the artery that provides the vascular supply to the affected area (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15019125','lexi-content-ref-8540974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15019125','lexi-content-ref-8540974'])">Ref</a></span>). Pain usually resolves by the end of the infusion; repeat if pain recurs. <b>This intervention should be used only by those accustomed to this technique. Extreme care should be taken to avoid the extravasation.</b> A poison information center or clinical toxicologist should be consulted prior to implementation.</p>
<p style="text-indent:-2em;margin-left:4em;">Inhalation: 2.5% nebulization solution: Mix 1.5 <b>mL</b> of 10% calcium gluconate solution with 4.5 mL NS to make a 2.5% solution and administer via nebulization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2401930']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2401930'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c45c9b2-5b99-4a30-8d18-9aa9cc8cb6fd">Hyperkalemia, adjunctive treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia, adjunctive treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Calcium is administered for myocardium stabilization and prevention of arrhythmias; must be used in conjunction with therapy to shift potassium intracellularly and/or eliminate potassium.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Dose expressed as <b>calcium gluconate</b>: IV, Intraosseous: 60 to 100 mg/kg/<b>dose</b>; maximum dose: 2,000 mg/<b>dose</b>; may repeat if necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="adf422c8-4aea-4226-a44e-5748178792ab">Hypocalcemia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypocalcemia, treatment</b>: Dose depends on clinical condition and serum calcium concentration; monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Asymptomatic: </i>Limited data available: Infants, Children, and Adolescents: Dose expressed as <b>elemental calcium</b>: Oral: 30 to 75 mg/kg/day in 4 to 5 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lynch.1','lexi-content-ref-Root.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lynch.1','lexi-content-ref-Root.1'])">Ref</a></span>). <b>Note:</b> In general, other oral calcium salts (eg, carbonate, glubionate) are a more preferable oral dosage form option in young pediatric patients; however, the 10% calcium gluconate injection may be given orally (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7836618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7836618'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to moderate symptoms:</i></p>
<p style="text-indent:-2em;margin-left:6em;">IV Intermittent:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents &lt;17 years: Dose expressed as <b>calcium gluconate</b>: IV: 29 to 60 mg/kg/<b>dose</b> every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≥17 years: Dose expressed as <b>calcium gluconate</b>: IV: 1,000 to 2,000 mg/<b>dose</b> every 6 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV Infusion:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents &lt;17 years: Initial: Dose expressed as <b>calcium gluconate</b>: IV: 8 to 13 mg/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents ≥17 years: Initial: Dose expressed as <b>calcium gluconate</b>: IV: 5.4 to 21.5 mg/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe symptoms (eg, seizures, tetany):</i> Infants, Children, and Adolescents: Dose expressed as <b>calcium gluconate</b>: IV, Intraosseous: 100 to 200 mg/kg/<b>dose</b> over 5 to 10 minutes, maximum dose: 1,000 to 2,000 mg/<b>dose</b>; may repeat as needed or follow with a continuous IV infusion of 8 to 32 mg/kg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-2372181','lexi-content-ref-21841146','lexi-content-ref-18676559','lexi-content-ref-19411338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-2372181','lexi-content-ref-21841146','lexi-content-ref-18676559','lexi-content-ref-19411338'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="71988c4f-1929-4cb5-842d-f039c8b31808">Parenteral nutrition, maintenance calcium requirement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition, maintenance calcium requirement</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15568296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15568296'])">Ref</a></span>): <b>Note:</b> Dose expressed as <b>elemental calcium:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children ≤50 kg: IV: 0.5 to 4 <b>mEq</b>/kg/day as an additive to parenteral nutrition solution.</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;50 kg and Adolescents: IV: 10 to 20 <b>mEq</b>/day as an additive to parenteral nutrition solution.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ffe3e421-0969-4620-8970-895e92ca982d">Rickets, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rickets, treatment:</b> Limited data available: <b>Note:</b> Treatment should also include adequate vitamin D supplementation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25266429','lexi-content-ref-26741135']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25266429','lexi-content-ref-26741135'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Dose expressed as <b>elemental calcium</b>: Oral: 30 to 75 mg/kg/day in 3 divided doses; begin at higher end of range and titrate downward over 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18676559','lexi-content-ref-Root.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18676559','lexi-content-ref-Root.1'])">Ref</a></span>). <b>Note:</b> In general, other oral calcium salts (eg, carbonate, glubionate) are a more preferable oral dosage formulation option in young pediatric patients; however, the 10% calcium gluconate injection may be given orally (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7836618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7836618'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51083796"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Initiate at the lowest dose of the recommended dosage range; monitor serum calcium concentrations closely. Accumulation may occur with renal impairment and subsequent doses may require adjustment based on serum calcium concentrations.</p></div>
<div class="block dohp drugH1Div" id="F51083797"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">No initial dosage adjustment necessary; subsequent doses should be guided by serum calcium concentrations. Hepatic function does not affect the availability of ionized calcium after calcium gluconate administration.</p></div>
<div class="block doa drugH1Div" id="F144662"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9190" href="/d/html/9190.html" rel="external">see "Calcium gluconate: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: Dosages are expressed in terms of the <span style="text-decoration: underline">calcium gluconate salt</span> (unless otherwise specified as elemental calcium). Dosages expressed in terms of the <span style="text-decoration: underline">calcium gluconate salt</span> are based on a solution concentration of 100 mg/mL (10%) containing 0.465 mEq (9.3 mg) elemental calcium per mL, except where noted.</b> One gram of calcium gluconate salt is equal to 93 mg of elemental calcium.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5914c62-3220-46b2-be0c-d96b19443139">Beta-blocker overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Beta-blocker overdose (off-label use):</b> Based on limited data: <b>IV:</b> Initial: 60 <b>mg/kg</b> over 5 to 10 minutes (maximum: 3 to 6 <b>g/dose</b>); may repeat every 10 to 20 minutes for 3 to 4 additional doses <b>or</b> initiate a continuous infusion of 60 to 120 <b>mg/kg/hour</b> titrated to improve hemodynamic response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956228','lexi-content-ref-15898828','lexi-content-ref-17482022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956228','lexi-content-ref-15898828','lexi-content-ref-17482022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c249f3aa-2980-4cf2-b10a-11628f338aea">Calcium channel blocker overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calcium channel blocker overdose (off-label use):</b> Based on limited data: <b>IV:</b> Initial: 60 <b>mg/kg</b> over 5 to 10 minutes (maximum: 3 to 6 <b>g/dose</b>); may repeat every 10 to 20 minutes for 3 to 4 additional doses <b>or</b> initiate a continuous infusion of 60 to 120 <b>mg/kg/<b>hour</b></b> titrated to improve hemodynamic response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30412709','lexi-content-ref-20956228','lexi-content-ref-15898828','lexi-content-ref-17482022','lexi-content-ref-27749343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30412709','lexi-content-ref-20956228','lexi-content-ref-15898828','lexi-content-ref-17482022','lexi-content-ref-27749343'])">Ref</a></span>). In one report, 18 <b>g</b> was administered over a 3-hour period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8107735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8107735'])">Ref</a></span>). <b>Note:</b> Some recommend maintaining serum ionized calcium at a goal of twice normal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17482022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17482022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="218a5213-a03c-48f3-b08c-fef2754f2217">Calcium replacement, during CRRT with citrate-based regional anticoagulation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Calcium replacement, during CRRT with citrate-based regional anticoagulation (off-label use)</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intracircuit, posthemodialysis filter (returning to the patient) or IV through a separate central line:</b> Ensure adequate systemic ionized calcium concentrations (drawn directly from the patient) prior to initiation of CRRT. During CRRT, use a calcium gluconate continuous infusion sliding scale to maintain systemic ionized calcium between ~3.6 to 5.2 mg/dL (~0.9 to 1.3 mmol/L); monitor systemic ionized calcium every 6 hours (or more frequently when indicated) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19690224','lexi-content-ref-27866200','lexi-content-ref-29151020','lexi-content-ref-17699194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19690224','lexi-content-ref-27866200','lexi-content-ref-29151020','lexi-content-ref-17699194'])">Ref</a></span>). Refer to institutional protocols.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2aced19d-8e31-42bf-bea8-4f1531ddba82">Cardiac arrest or cardiotoxicity in the presence of hypocalcemia or hypermagnesemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cardiac arrest or cardiotoxicity in the presence of hypocalcemia or hypermagnesemia: Note:</b> Routine use in cardiac arrest is not recommended due to the lack of improved survival (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529','lexi-content-ref-34847226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529','lexi-content-ref-34847226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Intraosseous:</b> 1.5 to 3 g as a rapid bolus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956228','lexi-content-ref-34847226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956228','lexi-content-ref-34847226'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="20b6999a-0990-4a13-a395-5b9144f1b648">Hydrofluoric acid exposure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hydrofluoric acid exposure (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Systemic toxicity, prevention and treatment:</i> Note:</b> Profound and precipitous hypocalcemia may occur after exposure to higher hydrofluoric acid concentrations to even a small surface area (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21171855']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21171855'])">Ref</a></span>). Additional treatment measures may be required (eg, magnesium) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Su.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Su.1'])">Ref</a></span>); consultation with a clinical toxicologist or poison control center is highly recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 2 g immediately or as soon as possible after exposure (before serum calcium level is known). Monitor serum calcium level; if serum calcium level is not within normal range, then give an additional 1 g, followed by 4 g over 1 hour, as needed, to maintain serum calcium levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15019125']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15019125'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Hydrofluoric acid burns, treatment:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Topical:</b> 2.5% gel: After washing the affected area, apply liberally and allow the application to stay on the affected area for ≥30 minutes or for ≥15 minutes past the point of pain resolution, whichever is longer; cover and redress every 4 hours as needed. <b>Note:</b> Surgical gloves filled with gel are useful for hand burns (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8540974','lexi-content-ref-24946967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8540974','lexi-content-ref-24946967'])">Ref</a></span>). The use of gel-filled condom for penile exposure has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17849253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17849253'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note:</b> If commercially available or extemporaneously compounded gel is unavailable, then topical application of wet compresses made with the 10% calcium gluconate IV solution may be used immediately following decontamination (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29310404','lexi-content-ref-26188892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29310404','lexi-content-ref-26188892'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>SUBQ (off-label route):</b> 5% to 10% solution: 0.5 <b>mL</b>/cm<sup>2</sup> of burned tissue (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5479482','lexi-content-ref-15019125','lexi-content-ref-8540974','lexi-content-ref-Krenzelok.1999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5479482','lexi-content-ref-15019125','lexi-content-ref-8540974','lexi-content-ref-Krenzelok.1999'])">Ref</a></span>). Infiltration should be carried 0.5 cm away from the margin of the injured tissue into the surrounding uninjured areas. Repeat if pain recurs. Local anesthesia may be required to perform procedure; pain resolution is the therapeutic endpoint and if a local anesthetic is utilized, it may be difficult to determine the success of therapy (<b>Note: Never</b> use calcium chloride for SUBQ injection as it may result in severe dermal necrosis).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Intra-arterial (off-label route):</b> Add 1 g (10 <b>mL</b> of a 10% solution) to 50 mL of D5W. Infuse over 4 hours into the artery that provides the vascular supply to the affected area (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15019125','lexi-content-ref-8540974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15019125','lexi-content-ref-8540974'])">Ref</a></span>). Pain usually resolves by the end of the infusion; repeat if pain recurs. <b>This intervention should be used only by those accustomed to this technique. Extreme care should be taken to avoid the extravasation.</b> A poison information center or clinical toxicologist should be consulted prior to implementation.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV (Bier block technique) (off-label route):</b> Add 1.5 g (15 <b>mL</b> of a 10% solution) to 35 mL of NS and infuse over 2 minutes using a Bier block technique (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24418646']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24418646'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Hydrofluoric acid inhalational exposure, treatment:</i> Inhalation (off-label route):</b> 2.5% nebulization solution: Mix 1.5 <b>mL</b> of 10% calcium gluconate solution with 4.5 mL NS to make a 2.5% solution and administer via nebulization; repeat doses may be given after medical evaluation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32209280','lexi-content-ref-2401930','lexi-content-ref-24946967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32209280','lexi-content-ref-2401930','lexi-content-ref-24946967'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="637f3b98-5df7-446f-8c61-563a0b944ec9">Hyperkalemia, severe/emergent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia</b>
<b>, severe/emergent (off-label use): Note: </b>Use in patients with hyperkalemia-associated ECG changes <b>or</b> serum potassium &gt;6.5 mEq/L (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31706619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31706619'])">Ref</a></span>). Stabilizes myocardial cell membrane without impacting plasma potassium concentrations; must combine with insulin/dextrose to decrease plasma potassium levels and other therapies to eliminate potassium from body (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529'])">Ref</a></span>). Perform continuous cardiac monitoring and obtain serial ECGs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31706619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31706619'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV, Intraosseous:</b> Initial: 1 to 2 g over 2 to 5 minutes; may repeat after 5 minutes if ECG changes persist or recur, then every 30 to 60 minutes as needed; usual initial dosage range: 1 to 3 g (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33081529','lexi-content-ref-Mount.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33081529','lexi-content-ref-Mount.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="56b78d57-43d2-4027-974d-ac61278c73a0">Hypocalcemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypocalcemia: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use in patients with severe symptoms of hypocalcemia (eg, tetany, seizures, carpopedal spasm), ECG abnormalities (eg, QTc prolongation, arrhythmia), or an acute decrease in albumin-corrected serum calcium levels to &lt;7 to 7.5 mg/dL (&lt;1.75 to 1.87 mmol/L) when serious complications may occur if untreated (eg, following neck surgery). Should also be used in patients whose symptoms did not improve with or who can no longer take oral calcium. Correct concurrent hypomagnesemia if present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26938200','lexi-content-ref-22439169','lexi-content-ref-Goltzman.1','lexi-content-ref-27935815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26938200','lexi-content-ref-22439169','lexi-content-ref-Goltzman.1','lexi-content-ref-27935815'])">Ref</a></span>). <b>Do not</b> use IV calcium as initial therapy in patients with chronic kidney disease who are asymptomatic or who have stable hypocalcemia with only mild symptoms (eg, paresthesias) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goltzman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goltzman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial bolus dose(s):</i>
<b>IV: </b>Add 1 or 2 g (10 or 20 <b>mL</b> of a 10% solution) to 50 mL of D5W or NS (equivalent to ~90 or ~180 mg <b>elemental calcium</b>). Infuse over 10 to 20 minutes; may repeat bolus dose after 10 to 60 minutes if symptoms persist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26938200','lexi-content-ref-Goltzman.1','lexi-content-ref-27935815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26938200','lexi-content-ref-Goltzman.1','lexi-content-ref-27935815'])">Ref</a></span>). If hypocalcemia is expected to persist (eg, hypoparathyroidism, pancreatitis), follow bolus dose(s) with a continuous IV calcium infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26938200','lexi-content-ref-22475676','lexi-content-ref-27935815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26938200','lexi-content-ref-22475676','lexi-content-ref-27935815'])">Ref</a></span>). <b>Note:</b> In patients with chronic hypocalcemia who require IV therapy, may initiate therapy with a continuous IV infusion and omit bolus dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goltzman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goltzman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Continuous infusion:</i>
<b>IV</b>
<b>:</b> Add 11 g (110 <b>mL</b> of a 10% solution) to 890 mL of D5W or NS (equivalent to ~1 g <b>elemental calcium</b> in a final total volume of 1,000 mL). Initiate infusion at 50 to 100 mL/hour (equivalent to ~50 to 100 mg/hour of <b>elemental calcium</b>; adjust dose to maintain albumin-corrected serum calcium levels at the low end of normal. Initiate oral calcium and vitamin D supplements as soon as possible; once an effective oral regimen is achieved, taper IV calcium infusion slowly (eg, over 24 to 48 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26938200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26938200'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e69afa9e-557e-43f1-9b39-f55cc1e5831e">Parenteral nutrition, maintenance requirement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition, maintenance requirement:</b>
<b>Note:</b> Expressed in terms of <b>elemental calcium:</b>
<b>IV: </b>10 to 15 <b>mEq elemental calcium</b> daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ASPEN.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ASPEN.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f44a01c8-1397-4b39-b31c-d98ad613fd8e">Radium-226 or strontium-90 internal contamination</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Radium-226 or strontium-90 internal contamination</b>
<b>(off-label use): IV:</b> 2.5 g in 500 mL D5W over 4 to 6 hours once daily for up to 6 days; if possible, administer within 12 hours of radionuclide intake (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2022'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991275"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: Do not </b>use IV calcium as initial therapy in patients with chronic kidney disease who are asymptomatic or who have stable hypocalcemia with only mild symptoms (eg, paresthesias) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goltzman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goltzman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Initiate with the lower limit of the dosage range (accumulation may occur with kidney impairment and subsequent doses may require adjustment based on serum calcium concentrations).</p></div>
<div class="block doha drugH1Div" id="F50988565"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No initial dosage adjustment necessary; subsequent doses should be guided by serum calcium concentrations. In patients in the anhepatic stage of liver transplantation, equal rapid increases in ionized concentrations occur suggesting that calcium gluconate does not require hepatic metabolism for release of ionized calcium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2360741']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2360741'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F144637"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, cardiac arrhythmia, decreased blood pressure, syncope, vasodilation</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Cutaneous calcification</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Inflammation at injection site, tissue necrosis at injection site</p></div>
<div class="block coi drugH1Div" id="F144652"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypercalcemia; concomitant use of IV calcium gluconate with ceftriaxone in neonates (≤28 days of age).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F144634"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: Parenteral calcium is a vesicant; ensure proper catheter or needle position prior to and during infusion. Avoid extravasation; adverse events from extravasation can be devastating (eg, profound tissue necrosis). Monitor the IV site closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: Constipation, bloating, and gas are common with oral calcium supplements (especially carbonate salt).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperphosphatemia: Use with caution in patients with severe hyperphosphatemia as elevated levels of phosphorus and calcium may result in soft tissue and pulmonary arterial calcium-phosphate precipitation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Use with caution in patients with severe hypokalemia as acute rises in serum calcium levels may result in life-threatening cardiac arrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypomagnesemia: Hypomagnesemia is a common cause of hypocalcemia; therefore, correction of hypocalcemia may be difficult in patients with concomitant hypomagnesemia. Evaluate serum magnesium and correct hypomagnesemia (if necessary), particularly if initial treatment of hypocalcemia is refractory.</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney stones (calcium-containing): Use caution when administering calcium supplements to patients with a history of kidney stones.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with chronic renal failure to avoid hypercalcemia; frequent monitoring of serum calcium and phosphorus is necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register 2002). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate product selection: Multiple salt forms of calcium exist; close attention must be paid to the salt form when ordering and administering calcium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over or under dosing.</p>
<p style="text-indent:-2em;margin-left:4em;">• IV administration: Avoid too-rapid IV administration (do not exceed 200 mg/minute in adults and 100 mg/minute in pediatric patients), unless patient is in cardiac arrest; may result in vasodilation, hypotension, bradycardia, arrhythmias, syncope, and cardiac arrest.</p>
<p style="text-indent:-2em;margin-left:4em;">• Oral administration: Administering oral calcium with food and vitamin D will optimize calcium absorption.</p>
<p style="text-indent:-2em;margin-left:4em;">• Topical administration: Avoid contact with eyes; not for oral administration.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tartrazine: Some products may contain tartrazine, which may cause allergic reactions in susceptible individuals.</p></div>
<div class="block dosfc drugH1Div" id="F21879420"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">1 g calcium gluconate = elemental calcium 93 mg = calcium 4.65 mEq = calcium 2.33 mmol</p></div>
<div class="block foc drugH1Div" id="F144645"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10% (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10% (10 mL, 50 mL, 100 mL); 1 g in NaCl 0.8% (100 mL); Calcium gluconate 1 g/50 mL in NaCl 0.675% (50 mL); Calcium gluconate 2 g/100 mL in NaCl 0.675% (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg</p></div>
<div class="block geq drugH1Div" id="F144630"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323034"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Calcium Gluconate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10% (per mL): $0.58 - $0.65</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Calcium Gluconate-NaCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1GM/100ML 0.8% (per mL): $0.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1GM/50ML 0.675% (per mL): $0.47</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2GM/100ML 0.675% (per mL): $0.47</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866176"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10% (10 mL, 50 mL, 100 mL, 500 mL)</p></div>
<div class="block exp drugH1Div" id="F56922262"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">A calcium gluconate gel may be made with tablets or solution for injection. Crush seven calcium gluconate 500 mg tablets in a mortar and reduce to a fine powder and add a 5 oz (150 mL) tube of water-soluble surgical lubricant (eg, K-Y Jelly). Alternatively, add 2.5 g (25 mL) of calcium gluconate 10% solution for injection to 2.5 oz (75 mL) of water-soluble surgical lubricant (eg, K-Y Jelly). Calcium carbonate may be substituted; do not use calcium chloride due to the potential for irritation and further tissue injury (McKee 2014; Su 2011).</p></div>
<div class="block adip drugH1Div" id="F53565669"><span class="drugH1">Additional Information</span>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Elemental Calcium Content of Calcium Salts</b></caption>
<colgroup><col/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Calcium Salt</p></th>
<th align="center">
<p style="text-indent:0em;">Elemental Calcium</p>
<p style="text-indent:0em;">(mg/1 g of salt form)</p></th>
<th align="center">
<p style="text-indent:0em;">Calcium</p>
<p style="text-indent:0em;">(mEq/g)</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium acetate</p></td>
<td align="center">
<p style="text-indent:0em;">253</p></td>
<td align="center">
<p style="text-indent:0em;">12.7</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium carbonate</p></td>
<td align="center">
<p style="text-indent:0em;">400</p></td>
<td align="center">
<p style="text-indent:0em;">20</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium chloride</p></td>
<td align="center">
<p style="text-indent:0em;">273</p></td>
<td align="center">
<p style="text-indent:0em;">13.6</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium citrate</p></td>
<td align="center">
<p style="text-indent:0em;">211</p></td>
<td align="center">
<p style="text-indent:0em;">10.5</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium glubionate</p></td>
<td align="center">
<p style="text-indent:0em;">63.8</p></td>
<td align="center">
<p style="text-indent:0em;">3.2</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium gluconate</p></td>
<td align="center">
<p style="text-indent:0em;">93</p></td>
<td align="center">
<p style="text-indent:0em;">4.65</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Calcium lactate</p></td>
<td align="center">
<p style="text-indent:0em;">130</p></td>
<td align="center">
<p style="text-indent:0em;">6.5</p></td></tr></tbody></table></div>
<div class="block admp drugH1Div" id="F52612349"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer with plenty of fluids with or following meals. The 10% calcium gluconate injection may be administered orally in young pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7836618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7836618'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Do not inject calcium salts IM or administer SUBQ since severe necrosis and sloughing may occur; extravasation of calcium can result in severe necrosis and tissue sloughing. Do not use scalp vein or small hand or foot veins for IV administration. Not for endotracheal administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Intermittent IV infusion: Vial must be diluted prior to administration; if using premix solution, do not dilute. Infuse dose slowly (not to exceed 100 mg/minute), except in emergency situations; administer through a secure IV line to avoid extravasation, dermal calcium deposits, or tissue necrosis. In acute situations of symptomatic hypocalcemia, infusions over 5 to 10 minutes have been described in pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21841146','lexi-content-ref-18676559']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21841146','lexi-content-ref-18676559'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Vial must be diluted prior to administration; if using premix solution, do not dilute. Adjust rate as needed based on serum calcium concentrations. Typical rates of administration may vary with indication; refer to institutional protocol.</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral nutrition solution: Calcium-phosphate stability in parenteral nutrition solutions is dependent upon the pH of the solution, temperature, and relative concentration of each ion. The pH of the solution is primarily dependent upon the amino acid concentration. The higher the percentage amino acids the lower the pH, the more soluble the calcium and phosphate. Individual commercially available amino acid solutions vary significantly with respect to pH lowering potential and consequent calcium phosphate compatibility; consult product specific labeling for additional information.</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Early/acute calcium extravasation: </i>If acute extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (See Management of Drug Extravasations for more details); remove needle/cannula; apply dry cold compresses; elevate extremity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15192356','lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15192356','lexi-content-ref-24420913'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Delayed calcium extravasation:</i> If delayed extravasation suspected, closely monitor site; most calcifications spontaneously resolve. However, if a severe manifestation of calcinosis cutis occurs, may initiate sodium thiosulfate antidote (See Management of Drug Extravasations for more details) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F144649"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with plenty of fluids with or following meals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> For bolus or continuous infusion. Administer bolus slowly (not to exceed 200 mg/minute). For patients in cardiac arrest, administer as a rapid bolus via a central line or intraosseous route (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956228','lexi-content-ref-34847226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956228','lexi-content-ref-34847226'])">Ref</a></span>). For continuous infusions, adjust rate as needed based on serum calcium levels. Typical rates of administration may vary with indication; refer to institutional protocol. Not for IM administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Vesicant; ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extravasation management:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Early/acute calcium extravasation</i>: If extravasation occurs, stop infusion immediately; leave needle/cannula in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry warm compresses; initiate hyaluronidase antidote (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32341081','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32341081','lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Hyaluronidase: <b>Intradermal or SUBQ:</b> Inject a total of 1 to 1.7 mL (15 units/mL) as 5 separate 0.2 to 0.3 mL injections (using a tuberculin syringe) around the site of extravasation; if IV catheter remains in place, administer intravenously through the infiltrated catheter; may repeat in 30 to 60 minutes if no resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6628223','lexi-content-ref-36938775','lexi-content-ref-Zenk.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Delayed calcium extravasation:</i> Closely monitor site; most calcifications spontaneously resolve. However, if a severe manifestation of calcinosis cutis occurs, may initiate sodium thiosulfate antidote.</p>
<p style="text-indent:-2em;margin-left:8em;">Sodium thiosulfate: IV: 12.5 g over 30 minutes, administered 3 times per week; may increase gradually to 25 g 3 times per week; monitor for non-anion gap acidosis, hypocalcemia, severe nausea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Hydrofluoric acid exposure (off label):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Hydrofluoric acid burns, treatment:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>SUBQ infiltration (off-label route):</i> Using a 27- or 30-gauge needle, approach the wound from the distal point of injury and infiltrate directly into the affected dermis and subcutaneous tissue. The infiltration should be carried 0.5 cm away from the margin of the injured tissue into the surrounding uninjured areas (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5479482']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5479482'])">Ref</a></span>). <b>Avoid excessive administration, as it can cause compartment syndrome and further exacerbate tissue damage.</b> Following subungual exposure, administer to the affected area via the lateral or volar route through the fat pad (under digital nerve block); administration may also require removal of the nailbed, splitting the distal nail from the nailbed, or trimming the nail to the nailbed to reach the affected area (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8540974','lexi-content-ref-2914038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8540974','lexi-content-ref-2914038'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Topical:</i> Massage into the affected area and cover with a dressing. For hand involvement, place hand in rubber glove filled with gel and bend fingers intermittently to ensure proper contact with gel. The use of gel-filled condom for penile exposure has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17849253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17849253'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intra-arterial (off-label route):</i> Requires radiology to place an arterial catheter in an artery supplying blood to the area of exposure; infuse over four hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3740574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3740574'])">Ref</a></span>). <b>This intervention should be used only by those accustomed to this technique. Care should be taken to avoid the extravasation.</b> A poison information center or clinical toxicologist should be consulted prior to implementation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Hydrofluoric acid</b>
<b> inhalational exposure, treatment:</b> Inhalation (off-label route):</i> Mix 1.5 <b>mL</b> of 10% calcium gluconate solution with 4.5 mL NS to make a 2.5% solution and administer via nebulization (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32209280','lexi-content-ref-2401930','lexi-content-ref-24946967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32209280','lexi-content-ref-2401930','lexi-content-ref-24946967'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F2847084"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Premixed solution: Store at 20°C to 25°C (68°F to 77°F). Do not freeze. Use within 60 days of removal from overwrap. Discard any unused portion.</p>
<p style="text-indent:-2em;margin-left:4em;">Vials: Store intact vials at 20°C to 25°C (68°F to 77°F). Do not freeze. Discard unused portion within 4 hours after initial puncture.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pharmacy supply of emergency antidotes:</i> Guidelines suggest that at least 30 g of calcium gluconate be stocked. Suggested amount is stated to be a sufficient quantity to provide antidotal treatment for 1 patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2018); actual amount to be stocked should take into account site-specific and population-specific needs.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Store at room temperature; consult product labeling for specific requirements.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical:</b> Gel: Calgonate: 2.5% (25 g): Store at 15°C to 30°C (59°F to 85°F). Open tube only when needed; discard open or damaged tubes.</p></div>
<div class="block usep drugH1Div" id="F53565807"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Treatment of acute symptomatic hypocalcemia (FDA approved in all ages); has also been used for calcium channel blocker toxicity, cardiac arrest, hyperkalemia, hypermagnesemia, hydrofluoric acid burns, rickets, and as a supplement in parenteral nutrition admixtures.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Dietary supplementation of calcium (OTC: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F144690"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Calcium gluconate may be confused with calcium glubionate, cupric sulfate</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Calcium gluconate may be confused with calcium chloride.</p>
<p style="text-indent:-2em;margin-left:4em;">Confusion with the different intravenous salt forms of calcium has occurred. There is a threefold difference in the primary cation concentration between <b>calcium gluconate</b> (in which 1 g = 4.65 mEq [93 mg] of elemental Ca++) and <b>calcium chloride</b> (in which 1 g = 14 mEq [270 mg] of elemental Ca++).</p>
<p style="text-indent:-2em;margin-left:4em;">Prescribers should specify which salt form is desired. To prevent medication errors, dosages should be expressed either as mg or grams of the salt form for most indications. Dosages expressed as mEq may be used for nutrition.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298941"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F144639"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: Calcium Salts may decrease the absorption of Alpha-Lipoic Acid. Alpha-Lipoic Acid may decrease the absorption of Calcium Salts.  Management: Separate administration of alpha-lipoic acid from that of any calcium-containing compounds by several hours. If alpha-lipoic acid is given 30 minutes before breakfast, then administer oral calcium-containing products at lunch or dinner.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baloxavir Marboxil: Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bictegravir: Calcium Salts may decrease the serum concentration of Bictegravir.  Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered with calcium salts under fed conditions, but coadministration with or 2 hours after a calcium salt is not recommended under fasting conditions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabotegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Cabotegravir.  Management: Administer polyvalent cation containing products at least 2 hours before or 4 hours after oral cabotegravir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Calcium Salts may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CefTRIAXone: Calcium Salts (Intravenous) may enhance the adverse/toxic effect of CefTRIAXone. Ceftriaxone binds to calcium forming an insoluble precipitate.  Management: Use of ceftriaxone is contraindicated in neonates (28 days of age or younger) who require (or are expected to require) treatment with IV calcium-containing solutions. In older patients, flush lines with compatible fluid between administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Polyvalent Cation Containing Products may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Calcium Salts may decrease the serum concentration of Dolutegravir.  Management: Administer dolutegravir at least 2 hours before or 6 hours after oral calcium. Administer dolutegravir/rilpivirine at least 4 hours before or 6 hours after oral calcium salts. Alternatively, dolutegravir and oral calcium can be taken together with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: Polyvalent Cation Containing Products may decrease the serum concentration of Eltrombopag.  Management: Administer eltrombopag at least 2 hours before or 4 hours after oral administration of any polyvalent cation containing product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Elvitegravir.  Management: Administer elvitegravir 2 hours before or 6 hours after the administration of polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estramustine: Calcium Salts may decrease the absorption of Estramustine.  Management: Administer estramustine on an empty stomach, at least 1 hour before or 2 hours after the dose of an oral calcium supplement. If coadministered with calcium salts, monitor for decreased estramustine therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Calcium Salts may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May increase the serum concentration of Calcium Salts. Calcium Salts may decrease the serum concentration of Multivitamins/Fluoride (with ADE). More specifically, calcium salts may impair the absorption of fluoride. Management: Avoid eating or drinking dairy products or consuming vitamins or supplements with calcium salts one hour before or after of the administration of fluoride.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PenicillAMINE: Polyvalent Cation Containing Products may decrease the serum concentration of PenicillAMINE.  Management: Separate the administration of penicillamine and oral polyvalent cation containing products by at least 1 hour.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.  Management: This applies only to oral phosphate and calcium administration. Administering oral phosphate supplements as far apart from the administration of an oral calcium salt as possible may be able to minimize the significance of the interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: Calcium Salts may decrease the absorption of Quinolones. Of concern only with oral administration of both agents.  Management: Consider administering an oral quinolone at least 2 hours before or 6 hours after the dose of oral calcium to minimize this interaction. Monitor for decreased therapeutic effects of quinolones during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: Polyvalent Cation Containing Products may decrease the serum concentration of Raltegravir.  Management: Administer raltegravir 2 hours before or 6 hours after administration of the polyvalent cations. Dose separation may not adequately minimize the significance of this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxadustat: Polyvalent Cation Containing Products may decrease the serum concentration of Roxadustat.  Management: Administer roxadustat at least 1 hour after the administration of oral polyvalent cation containing products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: Calcium Salts may decrease the serum concentration of Tetracyclines.  Management: If coadministration of oral calcium with oral tetracyclines cannot be avoided, consider separating administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May increase the serum concentration of Calcium Salts.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours. Monitor for decreased therapeutic effects of thyroid products if an oral calcium supplement is initiated/dose increased.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trientine: Polyvalent Cation Containing Products may decrease the serum concentration of Trientine.  Management: Avoid concomitant use of trientine and polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. For other oral polyvalent cations, give trientine 1 hour before, or 1 to 2 hours after the polyvalent cation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Unithiol: May diminish the therapeutic effect of Polyvalent Cation Containing Products.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs. <i> Risk C: Monitor therapy</i></p></div>
<div class="block dic drugH1Div" id="F50961845"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary reference intake for calcium (IOM 2011):</b></p>
<p style="text-indent:-2em;margin-left:4em;">0 to &lt;6 months: Adequate intake: 200 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:4em;">6 to 12 months: Adequate intake: 260 mg <b>elemental calcium</b>/day.</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 3 years: Recommended dietary allowance (RDA): 700 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:4em;">4 to 8 years: RDA: 1,000 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:4em;">9 to 18 years: RDA: 1,300 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:4em;">19 to 50 years: RDA: 1,000 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:4em;">51 to 70 years: RDA:</p>
<p style="text-indent:-2em;margin-left:6em;">Females: 1,200 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:6em;">Males: 1,000 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;70 years: RDA: 1,200 mg <b>elemental calcium/</b>day.</p>
<p style="text-indent:-2em;margin-left:4em;">Pregnancy/Lactating: RDA: Requirements are the same as in nonpregnant or nonlactating females.</p></div>
<div class="block pri drugH1Div" id="F1891176"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Calcium crosses the placenta. The amount of calcium reaching the fetus is determined by maternal physiological changes (IOM 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Calcium requirements are the same in pregnant patients and nonpregnant females (IOM 2011). Information related to use as an antidote in pregnancy is limited. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant patients if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the nonpregnant patient. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015).</p></div>
<div class="block mopp drugH1Div" id="F53565792"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum calcium (ionized calcium preferred if available) every 4 to 6 hours (during intermittent infusion; monitor every 4 hours for patients with renal impairment), every 1 to 4 hours (during continuous infusion), phosphate, magnesium, vital signs, and ECG. Monitor infusion site for extravasation.</p></div>
<div class="block rerp drugH1Div" id="F53565671"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Ranges may slightly vary by individual laboratories.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:left;">
<b>Normal Calcium Values (Lo 2020)</b></caption>
<colgroup><col align="center"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="center"></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">Age</p></th>
<th align="center" valign="middle">
<p style="text-indent:0em;">Serum Concentration</p></th></tr></thead>
<tbody>
<tr>
<td align="center" rowspan="6">
<p style="text-indent:0em;">Calcium, total</p></td>
<td align="left">
<p style="text-indent:0em;">Cord blood</p></td>
<td align="left">
<p style="text-indent:0em;">9 to 11.5 mg/dL (SI: 2.3 to 2.9 mmol/L)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Newborn 3 to 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">9 to 10.6 mg/dL (SI: 2.3 to 2.7 mmol/L)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Newborn 24 to 48 hours</p></td>
<td align="left">
<p style="text-indent:0em;">7 to 12 mg/dL (SI: 1.8 to 3 mmol/L)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">4 to 7 days</p></td>
<td align="left">
<p style="text-indent:0em;">9 to 10.9 mg/dL (SI: 2.3 to 2.7 mmol/L)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Child</p></td>
<td align="left">
<p style="text-indent:0em;">8.8 to 10.8 mg/dL (SI: 2.2 to 2.7 mmol/L)</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Adolescent to Adult</p></td>
<td align="left">
<p style="text-indent:0em;">8.4 to 10.2 mg/dL (SI: 2.1 to 2.6 mmol/L)</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Calcium, ionized, whole blood</p></td>
<td align="left">
<p style="text-indent:0em;">Cord blood</p></td>
<td align="left">
<p style="text-indent:0em;">5 to 6 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Newborn 3 to 24 hours</p></td>
<td align="left">
<p style="text-indent:0em;">4.3 to 5.1 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Newborn 24 to 48 hours</p></td>
<td align="left">
<p style="text-indent:0em;">4 to 4.7 mg/dL</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥2 days</p></td>
<td align="left">
<p style="text-indent:0em;">4.8 to 4.92 mg/dL (2.24 to 2.46 mEq/L)</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">In low albumin states if ionized calcium in unavailable, the corrected <b>total </b>serum calcium may be estimated by this equation (assuming a normal albumin of 4 g/dL [SI: 40 g/L]):</p>
<p style="text-indent:-2em;margin-left:4em;">Corrected total calcium (mg/dL) = measured serum calcium (mg/mL) + 0.8 (4 − measured serum albumin [g/dL])</p></div>
<div class="block pha drugH1Div" id="F144633"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Moderates nerve and muscle performance via action potential threshold regulation.</p>
<p style="text-indent:-2em;margin-left:2em;">In hydrogen fluoride exposures, calcium gluconate provides a source of calcium ions to complex free fluoride ions and prevent or reduce toxicity; administration also helps to correct fluoride-induced hypocalcemia.</p>
<p style="text-indent:-2em;margin-left:2em;">In patients with radium-226 (Ra-226) or strontium-90 internal contamination, calcium gluconate competes for bone binding sites and binds phosphate (REMM 2022).</p></div>
<div class="block phk drugH1Div" id="F144651"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Minimal unless chronic, high doses are given; predominantly in the duodenum and dependent on calcitriol and vitamin D; mean absorption of calcium intake varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, adults 25%); during pregnancy, calcium absorption doubles; calcium is absorbed in soluble, ionized form; solubility of calcium is increased in an acidic environment (IOM 2011); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Primarily in skeleton (99%)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~40%, primarily to albumin</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Primarily feces (75%; as unabsorbed calcium salts); urine (20%) (IOM 2011)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038547"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Calcio gluconato | Gluconato calcio | Gluconato de calcio</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Calcilin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Calcium | Gultate</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Gliconato de calcio | Gluconato de calcio</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Calcium glucon.co | Gai li de</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Gluconato de calcio</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ca d glukarat | Calciumgluconat fagron | Dobo | Dreisacal</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Gluconato de calcio | Gluconato de calcio Ecar</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Calcii gluconas | Kaltsium glukonaat | Kaltsiumglukonaat</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Calcii gluconas</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Gluconate de calcium b.braun medical | Gluconate de calcium cooper</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Calcimusc</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Calcio gluconato | Calcio gluconato monico</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Calcicol</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Glucal</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Daihan calcium gluconate | Jw calcium gluconate</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Calcii gluconas | Calcium gluconat | Calcium spofa</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Calcii gluconas | Calcium gluconase | Kalcija glikonats</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bon ker</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Calcium Gluconate B Braun | Radiance Boron</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Calcio gluconato | Glucal | Gluconato de calcio</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Calcinate | Harson calcium gluconate</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Calcio gluconato | Calcium gluconicum</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Gluconato de calcio Braun | Gluconato de calcio Labesfal</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Gluconato de calcio parafarma | Gluconato de calcio sanderson | Gluconato de calcio veinfar</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Calcium gluconate lekt</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Calcicon | Calcium</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Gluconate de calcium</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Calcium gluconated</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Calcii gluconas</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Gluconato de calcio | Gluconato de calcio icu vita | Gluconato de calcio sanderson</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Gluconato de calcio</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Freeda calcium gluconate | Gulf calcium gluconate | Kalci-300</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AHA.1">
<a name="AHA.1"></a>2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Part 10.1: Life-Threatening Electrolyte Abnormalities. <i>Circulation</i>. 2005;112:IV121–5.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23629620">
<a name="23629620"></a>Abrams SA, Committee on Nutrition. Calcium and vitamin D requirements of enterally fed preterm infants. <i>Pediatrics</i>. 2013;131(5):e1676-1683.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/23629620/pubmed" id="23629620" target="_blank">23629620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aluminum.1">
<a name="Aluminum.1"></a>Aluminum in large and small volume parenterals used in total parenteral nutrition. <i>Fed Regist</i>. 2002;67(244):77792-77793. To be codified at 21 CFR §201.323.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASPEN.1">
<a name="ASPEN.1"></a>American Society for Parenteral and Enteral Nutrition (ASPEN). Appropriate dosing for parenteral nutrition: ASPEN recommendations. https://www.nutritioncare.org/uploadedFiles/Documents/Guidelines_and_Clinical_Resources/PN%20Dosing%201-Sheet-Nov%202020-FINAL.pdf. Updated 2019. Accessed March 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15064673">
<a name="15064673"></a>Ariyan CE, Sosa JA. Assessment and Management of Patients With Abnormal Calcium. <i>Crit Care Med</i>. 2004;32(4)(suppl):146-154.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/15064673/pubmed" id="15064673" target="_blank">15064673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23942432">
<a name="23942432"></a>Balasubramanian S, Dhanalakshmi K, Amperayani S. Vitamin D deficiency in childhood-a review of current guidelines on diagnosis and management. <i>Indian Pediatr</i>. 2013;50(7):669-675. doi:10.1007/s13312-013-0200-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/23942432/pubmed" id="23942432" target="_blank">23942432</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.1">
<a name="expert.1"></a>Based on expert opinion.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31598101">
<a name="31598101"></a>Bartlett JW, Walker PL. Management of calcium channel blocker toxicity in the pediatric patient. <i>J Pediatr Pharmacol Ther</i>. 2019;24(5):378-389. doi:10.5863/1551-6776-24.5.378<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/31598101/pubmed" id="31598101" target="_blank">31598101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bentur.1">
<a name="Bentur.1"></a>Bentur Y, Biran I, Miller B. Evaluation of the Efficacy of 1% Calcium Gluconate in the Treatment of Hydrofluoric Acid (HF) Eye Burn. <i>Clin Toxicol</i>. 1995;33(5):535.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26938200">
<a name="26938200"></a>Bilezikian JP, Brandi ML, Cusano NE, et al. Management of hypoparathyroidism: present and future. <i>J Clin Endocrinol Metab</i>. 2016;101(6):2313-2324. doi:10.1210/jc.2015-3910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/26938200/pubmed" id="26938200" target="_blank">26938200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19690224">
<a name="19690224"></a>Burry LD, Tung DD, Hallett D, et al. Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy. <i>Ann Pharmacother</i>. 2009;43(9):1419-25. doi:10.1345/aph.1M182<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/19690224/pubmed" id="19690224" target="_blank">19690224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Calcium.1">
<a name="Calcium.1"></a>Calcium gluconate injection (premixed bags) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Calcium.2">
<a name="Calcium.2"></a>Calcium gluconate injection (vial) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Calcium.3">
<a name="Calcium.3"></a>Calcium gluconate injection (premixed bag) [prescribing information]. Paramus, NJ: WG Critical Care LLC; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Calcium.3">
<a name="Calcium.3"></a>Calcium gluconate injection (premixed bag) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32209280">
<a name="32209280"></a>Choe MSP, Lee MJ, Seo KS, et al. Application of calcium nebulization for mass exposure to an accidental hydrofluoric acid spill. <i>Burns</i>. 2020;46(6):1337-1346. doi:10.1016/j.burns.2020.02.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/32209280/pubmed" id="32209280" target="_blank">32209280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31706619">
<a name="31706619"></a>Clase CM, Carrero JJ, Ellison DH, et al; Conference Participants. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney Int</i>. 2020;97(1):42-61. doi:10.1016/j.kint.2019.09.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/31706619/pubmed" id="31706619" target="_blank">31706619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15898828">
<a name="15898828"></a>DeWitt CR, Walsman JC. Pharmacology, Pathophysiology and Management of Calcium Channel Blocker and Beta-Blocker Toxicity. <i>Toxicol Rev</i>. 2004;23(4):223-238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/15898828/pubmed" id="15898828" target="_blank">15898828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5479482">
<a name="5479482"></a>Dibbell DG, Iverson RE, Jones W, et al. Hydrofluoric Acid Burns of the Hand. <i>J Bone Joint Surg Am</i>. 1970;52(5):931-936.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/5479482/pubmed" id="5479482" target="_blank">5479482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2372181">
<a name="2372181"></a>Edmondson S, Almquist TD. Iatrogenic hypocalcemic tetany. <i>Ann Emerg Med</i>. 1990;19(8):938-940.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/2372181/pubmed" id="2372181" target="_blank">2372181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Eichenwald EC. <i>Manual of Neonatal Care</i>. 8th edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22439169">
<a name="22439169"></a>Fong J, Khan A. Hypocalcemia: updates in diagnosis and management for primary care. <i>Can Fam Physician</i>. 2012;58(2):158-162.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/22439169/pubmed" id="22439169" target="_blank">22439169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22475676">
<a name="22475676"></a>French S, Subauste J, Geraci S. Calcium abnormalities in hospitalized patients. <i>Southern Med J</i>. 2012;105(4):231-237.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/22475676/pubmed" id="22475676" target="_blank">22475676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25266429">
<a name="25266429"></a>Golden NH, Abrams SA; Committee on Nutrition. Optimizing bone health in children and adolescents. <i>Pediatrics</i>. 2014;134(4):e1229-e1243. doi:10.1542/peds.2014-2173<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/25266429/pubmed" id="25266429" target="_blank">25266429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goltzman.1">
<a name="Goltzman.1"></a>Goltzman D. Treatment of hypocalcemia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Greenbaum.1">
<a name="Greenbaum.1"></a>Greenbaum LA. Vitamin D deficiency (rickets) and excess. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap. 64.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15019125">
<a name="15019125"></a>Hatzifotis M, Williams A, Muller M, et al. Hydrofluoric Acid Burns. <i>Burns</i>. 2004;30(2):156-159.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/15019125/pubmed" id="15019125" target="_blank">15019125</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-739173">
<a name="739173"></a>Heaney RP, Recker RR, Saville PD. Menopausal Changes in Calcium Balance Performance. <i>J Lab Clin Med</i>. 1978;92(6):953-963.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/739173/pubmed" id="739173" target="_blank">739173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7909677">
<a name="7909677"></a>Howarth DM, Dawson AH, Smith AJ, et al. Calcium Channel Blocking Drug Overdose: An Australian Series. <i>Hum Exp Toxicol</i>. 1994;13(3):161-166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/7909677/pubmed" id="7909677" target="_blank">7909677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15192356">
<a name="15192356"></a>Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/15192356/pubmed" id="15192356" target="_blank">15192356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine). <i>Dietary Reference Intakes for Calcium and Vitamin D</i>. The National Academies Press; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12101159">
<a name="12101159"></a>Isbister GK. Continuous Calcium Chloride Infusion for Massive Nifedipine Overdose. <i>Emerg Med J</i>. 2002;19(4):355-357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/12101159/pubmed" id="12101159" target="_blank">12101159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20737250">
<a name="20737250"></a>Jain A, Agarwal R, Sankar MJ, Deorari A, Paul VK. Hypocalcemia in the newborn. <i>Indian J Pediatr</i>. 2010;77(10):1123-1128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/20737250/pubmed" id="20737250" target="_blank">20737250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26443610">
<a name="26443610"></a>Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773. doi:10.1161/CIR.0000000000000300<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/26443610/pubmed" id="26443610" target="_blank">26443610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21841146">
<a name="21841146"></a>Kelly A, Levine MA. Hypocalcemia in the critically ill patient. <i>J Intensive Care Med</i>. 2013;28(3):166-177. doi:10.1177/0885066611411543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/21841146/pubmed" id="21841146" target="_blank">21841146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17482022">
<a name="17482022"></a>Kerns W 2nd. Management of beta-adrenergic blocker and calcium channel antagonist toxicity. <i>Emerg Med Clin North Am</i>. 2007;25(2):309-331.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/17482022/pubmed" id="17482022" target="_blank">17482022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8540974">
<a name="8540974"></a>Kirkpatrick JJ, Burd DAR. An Algorithmic Approach to the Treatment of Hydrofluoric Acid Burns. <i>Burns</i>. 1995;21(7):495-499.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/8540974/pubmed" id="8540974" target="_blank">8540974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27866200">
<a name="27866200"></a>Kirwan CJ, Hutchison R, Ghabina S, et al. Implementation of a simplified regional citrate anticoagulation protocol for post-dilution continuous hemofiltration using a bicarbonate buffered, calcium containing replacement solution. <i>Blood Purif</i>. 2016;42(4):349-355. doi:10.1159/000452755<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/27866200/pubmed" id="27866200" target="_blank">27866200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):876-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Konca.1">
<a name="Konca.1"></a>Konca Ç, Yıldızdaş RD, Sarı MY, Yükselmiş U, Horoz ÖÖ, Yılmaz HL. Evaluation of children poisoned with calcium channel blocker or beta blocker drugs. <i>Turk Arch Ped</i>. 2013;48:138-144.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Koo.1">
<a name="Koo.1"></a>Koo WWK, Tsang RC. Calcium and magnesium homeostasis. In: MacDonald MG, Seshia MMK, eds. <i>Avery's Neonatology - Pathophysiology and Management of the Newborn</i>. 7th ed. Lippincott Williams &amp; Wilkins; 2015:646-669.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Krenzelok.1999">
<a name="Krenzelok.1999"></a>Krenzelok EP. Hydrofluoric acid exposures. In: Sullivan JB, Krieger GR, eds. <i>Clinical Environmental Health and Toxic Exposures</i>. 2nd ed. Lippincott Williams &amp; Wilkins; 1999:798-806.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30412709">
<a name="30412709"></a>Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol.</i> 2018:S0735-1097(18)38985-X. doi:10.1016/j.jacc.2018.10.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/30412709/pubmed" id="30412709" target="_blank">30412709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11296202">
<a name="11296202"></a>Lam YM, Tse HF, Lau CP. Delayed Asystolic Cardiac Arrest After Diltiazem Overdose: Resuscitation With High Dose Intravenous Calcium. <i>Chest</i>. 2001;119(4):1280-1282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/11296202/pubmed" id="11296202" target="_blank">11296202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lo.1">
<a name="Lo.1"></a>Lo SF. Reference intervals for laboratory tests and procedures. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Saunders Elsevier; 2020:chap. 748.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8669723">
<a name="8669723"></a>Love JN, Hanfling D, Howell JM. Hemodynamic effects of calcium chloride in a canine model of acute propranolol intoxication. <i>Ann Emerg Med</i>. 1996;28(1):1-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/8669723/pubmed" id="8669723" target="_blank">8669723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8107735">
<a name="8107735"></a>Lüscher TF, Noll G, Stürmer T, Huser B, Wenk M. Calcium gluconate in severe verapamil intoxication. <i>N Engl J Med</i>. 1994;330(10):718-720. doi:10.1056/NEJM199403103301019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/8107735/pubmed" id="8107735" target="_blank">8107735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lynch.1">
<a name="Lynch.1"></a>Lynch R, Wood EG, Neumayr TM. Fluid and electrolyte issues in pediatric critical illness. In: Fuhrman B, Zimmerman J, eds.<i> Pediatric Critical Care</i>. 5th ed. Elsevier Health; 2017:1007-1025.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6628223">
<a name="6628223"></a>MacCara ME. Extravasation: a hazard of intravenous therapy. <i>Drug Intell Clin Pharm</i>. 1983;17(10):713-717.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/6628223/pubmed" id="6628223" target="_blank">6628223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2360741">
<a name="2360741"></a>Martin TJ, Kang Y, Robertson KM, et al. Ionization and Hemodynamic Effects of Calcium Chloride and Calcium Gluconate in the Absence of Hepatic Function. <i>Anesthesiology</i>. 1990;73(1):62-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/2360741/pubmed" id="2360741" target="_blank">2360741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25114621">
<a name="25114621"></a>McKee D, Thoma A, Bailey K, Fish J. A review of hydrofluoric acid burn management. <i>Plast Surg (Oakv)</i>. 2014;22(2):95-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/25114621/pubmed" id="25114621" target="_blank">25114621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10215803">
<a name="10215803"></a>Millard TP, Harris AJ, MacDonald DM. Calcinosis Cutis Following Intravenous Infusion of Calcium Gluconate. <i>Br J Dermatol</i>. 1999;140(1):184-186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/10215803/pubmed" id="10215803" target="_blank">10215803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7836618">
<a name="7836618"></a>Mimouni F, Tsang RC. Neonatal hypocalcemia: to treat or not to treat? (A review). <i>J Am Coll Nutr</i>. 1994;13(5):408-415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/7836618/pubmed" id="7836618" target="_blank">7836618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15568296">
<a name="15568296"></a>Mirtallo J, Canada T, Johnson D, et al. Safe Practices for Parenteral Nutrition. <i>JPEN J Parenter Enteral Nutr</i>. 2004;28(6):S39-S70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/15568296/pubmed" id="15568296" target="_blank">15568296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18676559">
<a name="18676559"></a>Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M; Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. <i>Pediatrics</i>. 2008;122(2):398-417. doi:10.1542/peds.2007-1894<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/18676559/pubmed" id="18676559" target="_blank">18676559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12628894">
<a name="12628894"></a>Mokhlesi B, Leikin JB, Murray P, et al. Adult Toxicology in Critical Care: Part II: Specific Poisonings. <i>Chest</i>. 2003;123(3):897-922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/12628894/pubmed" id="12628894" target="_blank">12628894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mount.1">
<a name="Mount.1"></a>Mount DB. Treatment and prevention of hyperkalemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 9, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26741135">
<a name="26741135"></a>Munns CF, Shaw N, Kiely M, et al. Global consensus recommendations on prevention and management of nutritional rickets. <i>Horm Res Paediatr</i>. 2016;85(2):83-106. doi:10.1159/000443136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/26741135/pubmed" id="26741135" target="_blank">26741135</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1">
<a name="Nelson.1"></a>Nelson LS, Howland, MA, Lewin NA, et al, eds. <i>Goldfrank's Toxicologic Emergencies</i>, 11th ed. McGraw-Hill Education; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Neumar.1">
<a name="Neumar.1"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):729-767.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pai.1">
<a name="Pai.1"></a>Pai AB. Chapter 59: Disorders of Calcium and Phosphorus Homeostasis. <i>Pharmacotherapy: A Pathophysiologic Approach</i>. 8th ed. Talbert RL, DiPiro JT, Matzke GR, et al, eds. McGraw-Hill; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10231464">
<a name="10231464"></a>Palsson R, Niles JL. Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. <i>Kidney Int</i>. 1999;55(5):1991-1997.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/10231464/pubmed" id="10231464" target="_blank">10231464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33081529">
<a name="33081529"></a>Panchal AR, Bartos JA, Cabañas JG, et al; Adult basic and advanced life support writing group. Part 3: adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2020;142(16)(suppl 2):S366-S468. doi:10.1161/CIR.0000000000000916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/33081529/pubmed" id="33081529" target="_blank">33081529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1793522">
<a name="1793522"></a>Pearigen PD, Benowitz NL. Poisoning Due to Calcium Antagonists: Experience With Verapamil, Diltiazem, and Nifedipine. <i>Drug Saf</i>. 1991;6(6):408-430.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/1793522/pubmed" id="1793522" target="_blank">1793522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-709264">
<a name="709264"></a>Perkins CM. Serious verapamil poisoning: treatment with intravenous calcium gluconate. <i>Br Med J</i>. 1978;2(6145):1127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/709264/pubmed" id="709264" target="_blank">709264</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9624322">
<a name="9624322"></a>Pertoldi F, D'Orlando L, Mercante WP. Electromechanical dissociation 48 hours after atenolol overdose: usefulness of calcium chloride. <i>Ann Emerg Med</i>. 1998;31(6):777-781.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/9624322/pubmed" id="9624322" target="_blank">9624322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29310404">
<a name="29310404"></a>Pu Q, Qian J, Tao W, Yang A, Wu J, Wang Y. Extracorporeal membrane oxygenation combined with continuous renal replacement therapy in cutaneous burn and inhalation injury caused by hydrofluoric acid and nitric acid. <i>Medicine (Baltimore)</i>. 2017;96(48):e8972. doi:10.1097/MD.0000000000008972<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/29310404/pubmed" id="29310404" target="_blank">29310404</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8427431">
<a name="8427431"></a>Ramoska EA, Spiller HA, Winter M, Borys D. A one-year evaluation of calcium channel blocker overdoses: toxicity and treatment. <i>Ann Emerg Med</i>. 1993;22(2):196-200.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/8427431/pubmed" id="8427431" target="_blank">8427431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4000241">
<a name="4000241"></a>Recker RR. Calcium Absorption and Achlorhydria. <i>N Engl J Med</i>. 1985;313(2):70-73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/4000241/pubmed" id="4000241" target="_blank">4000241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17577338">
<a name="17577338"></a>Rigo J, Pieltain C, Salle B, Senterre J. Enteral calcium, phosphate and vitamin D requirements and bone mineralization in preterm infants. <i>Acta Paediatrica</i>. 2007;96:969-974.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/17577338/pubmed" id="17577338" target="_blank">17577338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2914038">
<a name="2914038"></a>Roberts JR, Merigian KS. Acute Hydrofluoric Acid Exposure. <i>Am J Emerg Med</i>. 1989;7(1):125-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/2914038/pubmed" id="2914038" target="_blank">2914038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Root.1">
<a name="Root.1"></a>Root AW. Disorders of mineral metabolism II. Abnormalities of mineral homeostasis in the newborn, infant, child, and adolescent. In: Sperling MA, ed. <i>Pediatric Endocrinology</i>. 5th ed. Elsevier; 2020:chap. 20.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-765441">
<a name="765441"></a>Root AW, Harrison HE. Recent advances in calcium metabolism. II. Disorders of calcium homeostasis. <i>J Pediatr</i>. 1976;88(2):177-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/765441/pubmed" id="765441" target="_blank">765441</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534324">
<a name="12534324"></a>Salhanick SD, Shannon MW. Management of Calcium Channel Antagonist Overdose. <i>Drug Saf</i>. 2003;26(2):65-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/12534324/pubmed" id="12534324" target="_blank">12534324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17849253">
<a name="17849253"></a>Schmidt MJ, Bryant SM. Hydrofluoric Acid Burn to Penis. <i>Clin Toxicol (Phila)</i>. 2007;45(6):732.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/17849253/pubmed" id="17849253" target="_blank">17849253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29151020">
<a name="29151020"></a>Schneider AG, Journois D, Rimmelé T. Complications of regional citrate anticoagulation: accumulation or overload? <i>Crit Care</i>. 2017;21(1):281. doi:10.1186/s13054-017-1880-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/29151020/pubmed" id="29151020" target="_blank">29151020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6716222">
<a name="6716222"></a>Scott SM, Ladenson JH, Aguanna JJ, Walgate J, Hillman LS. Effect of calcium therapy in the sick premature infant with early neonatal hypocalcemia. <i>J Pediatr</i>. 1984;104(5):747-751.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/6716222/pubmed" id="6716222" target="_blank">6716222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32341081">
<a name="32341081"></a>Smolders EJ, Benoist GE, Smit CCH, Ter Horst P. An update on extravasation: basic knowledge for clinical pharmacists. <i>Eur J Hosp Pharm</i>. 2020;28(3):165-167. doi:10.1136/ejhpharm-2019-002152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/32341081/pubmed" id="32341081" target="_blank">32341081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27749343">
<a name="27749343"></a>St-Onge M, Anseeuw K, Cantrell FL, et al. Experts consensus recommendations for the management of calcium channel blocker poisoning in adults. <i>Crit Care Med</i>. 2017;45(3):e306-e315. doi:10.1097/CCM.0000000000002087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/27749343/pubmed" id="27749343" target="_blank">27749343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy</i>. 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Su.1">
<a name="Su.1"></a>Su MK. Hyrdofluoric acid and fluorides. <i>Goldfrank's Toxicologic Emergencies</i>. 11th ed. Nelson LS, Howland MA, Lewin NA, Smith SW, Hoffman RS, eds. McGraw Hill; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17699194">
<a name="17699194"></a>Tolwani AJ, Prendergast MB, Speer RR, Stofan BS, Wille KM. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. <i>Clin J Am Soc Nephrol</i>. 2006;1(1):79-87. doi:10.2215/CJN.00040505<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/17699194/pubmed" id="17699194" target="_blank">17699194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Trujillo.1">
<a name="Trujillo.1"></a>Trujillo M, Guerrero J, Fragachan C, et al. Pharmacologic Antidotes in Critical Care Medicine: A Practical Guide for Drug Administration. <i>Crit Care Med</i>. 1998;26(2):377-391.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27935815">
<a name="27935815"></a>Turner J, Gittoes N, Selby P; Society for Endocrinology Clinical Committee. Society for Endocrinology endocrine emergency guidance: emergency management of acute hypocalcaemia in adult patients. <i>Endocr Connect</i>. 2016;5(5):G7-G8. doi:10.1530/EC-16-0056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/27935815/pubmed" id="27935815" target="_blank">27935815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2401930">
<a name="2401930"></a>Upfal M, Doyle C. Medical management of hydrofluoric acid exposure. <i>J Occup Med</i>. 1990;32(8):726-731.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/2401930/pubmed" id="2401930" target="_blank">2401930</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2022">
<a name="HHS.2022"></a>US Department of Health and Human Services (HHS) Radiation Emergency Medical Management (REMM). Managing internal radiation contamination. <a href="https://remm.hhs.gov/int_contamination.htm#blockingagents_2" target="_blank">https://remm.hhs.gov/int_contamination.htm#blockingagents_2</a>. Updated February 17, 2022. Accessed February 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34847226">
<a name="34847226"></a>Vallentin MF, Granfeldt A, Meilandt C, et al. Effect of intravenous or intraosseous calcium vs saline on return of spontaneous circulation in adults with out-of-hospital cardiac arrest: a randomized clinical trial. <i>JAMA</i>. 2021;326(22):2268-2276. doi:10.1001/jama.2021.20929<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/34847226/pubmed" id="34847226" target="_blank">34847226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3740574">
<a name="3740574"></a>Vance MV, Curry SC, Kunkel DB, et al. Digital Hydrofluoric Acid Burns: Treatment With Intraarterial Calcium Infusion. <i>Ann Emerg Med</i>. 1986;15(8):890-896.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/3740574/pubmed" id="3740574" target="_blank">3740574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956228">
<a name="20956228"></a>Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):829-861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/20956228/pubmed" id="20956228" target="_blank">20956228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31320908">
<a name="31320908"></a>Vuralli D. Clinical approach to hypocalcemia in newborn period and infancy: who should be treated?. <i>Int J Pediatr</i>. 2019;2019:4318075. doi:10.1155/2019/4318075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/31320908/pubmed" id="31320908" target="_blank">31320908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24946967">
<a name="24946967"></a>Wang X, Zhang Y, Ni L, et al. A review of treatment strategies for hydrofluoric acid burns: current status and future prospects. <i>Burns</i>. 2014;40(8):1447-1457. doi:10.1016/j.burns.2014.04.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/24946967/pubmed" id="24946967" target="_blank">24946967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5139991">
<a name="5139991"></a>Wills MR, Lewin MR. Plasma Calcium Fractions and the Protein-Binding of Calcium in Normal Subjects and in Patients With Hypercalcaemia and Hypocalcaemia. <i>J Clin Pathol</i>. 1971;24(9):856-866.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/5139991/pubmed" id="5139991" target="_blank">5139991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Worthley.1">
<a name="Worthley.1"></a>Worthley LI, Phillips PJ. Intravenous Calcium Salts. <i>Lancet</i>. 1980;2(8186):149.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21171855">
<a name="21171855"></a>Wu ML, Deng JF, Fan JS. Survival after hypocalcemia, hypomagnesemia, hypokalemia and cardiac arrest following mild hydrofluoric acid burn. <i>Clin Toxicol (Phila)</i>. 2010;48(9):953-955. doi:10.3109/15563650.2010.533676<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/21171855/pubmed" id="21171855" target="_blank">21171855</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23892993">
<a name="23892993"></a>Wu ML, Yang CC, Ger J, Tsai WJ, Deng JF. Acute hydrofluoric acid exposure reported to Taiwan Poison Control Center, 1991-2010. <i>Hum Exp Toxicol</i>. 2014;33(5):449-454. doi:10.1177/0960327113499165<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/23892993/pubmed" id="23892993" target="_blank">23892993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1737459">
<a name="1737459"></a>Zaloga GP. Hypocalcemia in critically ill patients. <i>Crit Care Med</i>. 1992;20(2):251-262.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/1737459/pubmed" id="1737459" target="_blank">1737459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zenk.1">
<a name="Zenk.1"></a>Zenk KE. Management of intravenous extravasations. <i>Infusion</i>. 1981;5(4):77-79.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26188892">
<a name="26188892"></a>Zhang Y, Wang X, Sharma K, et al. Injuries following a serious hydrofluoric acid leak: first aid and lessons. <i>Burns</i>. 2015;41(7):1593-1598. doi:10.1016/j.burns.2015.04.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/26188892/pubmed" id="26188892" target="_blank">26188892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24418646">
<a name="24418646"></a>Zhang Y, Wang X, Ye C, et al. The clinical effectiveness of the intravenous infusion of calcium gluconate for treatment of hydrofluoric acid burn of distal limbs. <i>Burns</i>. 2014;40(4):e26-e30. doi:10.1016/j.burns.2013.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/24418646/pubmed" id="24418646" target="_blank">24418646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19411338">
<a name="19411338"></a>Zhou P, Markowitz M. Hypocalcemia in infants and children. <i>Pediatr Rev</i>. 2009;30(5):190-192. doi:10.1542/pir.30-5-190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/calcium-gluconate-pediatric-drug-information/abstract-text/19411338/pubmed" id="19411338" target="_blank">19411338</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12956 Version 350.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
